Arecor Limited, the privately-owned biotech group, has dosed its first patient in a Phase I clinical trial for its second clinical-stage product, an ultra-concentrated rapid-acting insulin.
The product, AT278 is a new formulation of concentrated insulin (500U/mL) that acts rapidly and is quickly absorbed into the bloodstream from the site of injection.
Sarah Howell, Arecor’s chief executive, said: “The initiation of the Phase I clinical trial for AT278, is key to the advancement of our diabetes franchise of superior fast-acting insulins, focused on more personalised treatment regimens and sophisticated drug/device combinations.
“AT278 presents a significant step towards helping people with diabetes to maintain glucose control safely and conveniently.
“A concentrated rapid-acting insulin is a key enabler to delivering the next generation of miniaturized insulin delivery systems as well as providing a superior treatment and quality of life for people requiring large daily doses of insulin to manage their condition.”
Howell added that rapid-acting ultra-concentrated insulin is a critical unmet need to enable these next-generation delivery systems, in addition to reducing the number of daily injections for insulin-resistant patients requiring high doses of insulin.
Concentrated, rapid-acting insulin will reduce the number of injections required each day for high dose patients and enable patch pumps and smaller devices that improve patient adherence, particularly for children and teenagers.
“There is a real need to improve the delivery and control of insulins, and the type 1 diabetes community is looking forward to smaller devices that can help them maintain glucose control safely and conveniently,” said Jonathan Rosen, JDRF Associate Director of Research.
“JDRF supported the early development of AT278 as we believe that ultraconcentrated rapid-acting insulins will improve the overall quality of life for people living with type 1 diabetes and we look forward to the results of this Phase I clinical trial.”
Preliminary results from the trial, which is being carried out in Austria, are anticipated in the second half of 2021.